TABLE 2.
Summary of pharmacokinetic parameters for LB80331 following administration of single and multiple doses of LB80380 in CHB patients
| Dose (mg) | Single dose
|
Multiple doses
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-∞ (ng·h/ml) | Cmax (ng/ml) | Tmax (h)a | t1/2 (h) | CL/F (ml/min) | AUC0-∞/AUC0-24 (ng·h/ml) | Cmax (ng/ml) | Tmax (h)a | t1/2 (h) | CL/F (ml/min) | |
| 30 | 1,069 ± 371 | 200 ± 31 | 1.5 (1.0-3.0) | 2.5 ± 0.4 | 288 ± 83 | 1,069 ± 372 | 192 ± 46 | 2.0 (0.5-23.4) | 2.5 ± 0.7 | 289 ± 86 |
| 60 | 2,344 ± 221 | 397 ± 49 | 2.0 (1.0-2.0) | 3.0 ± 0.3 | 244 ± 24 | 2,105 ± 274 | 362 ± 74 | 2.0 (1.0-3.0) | 3.0 ± 0.5 | 273 ± 36 |
| 120 | 4,374 ± 994 | 805 ± 203 | 2.0 (0.5-2.0) | 3.0 ± 1.0 | 273 ± 75 | 3,838 ± 728 | 696 ± 156 | 1.0 (1.0-3.9) | 3.1 ± 0.4 | 304 ± 53 |
| 240 | 6,302 ± 582 | 1,076 ± 218 | 2.0 (1.0-3.9) | 3.0 ± 0.2 | 363 ± 37 | 5,656 ± 1,106 | 1,164 ± 242 | 2.0 (2.0-3.0) | 3.3 ± 0.2 | 416 ± 94 |
a
Tmax values are shown as medians, and the ranges are given in parentheses.